The Finnish national guideline for diagnosis, treatment and follow-up of patients with wet age-related macular degeneration (Q50903375)

25 March 2018

title

The Finnish national guideline for diagnosis, treatment and follow-up of patients with wet age-related macular degeneration (English)

1 reference

25 March 2018

0 references

Nina Hautala

1 reference

25 March 2018

author name string

Raimo Tuuminen

1 reference

25 March 2018

Hannele Uusitalo-Järvinen

1 reference

25 March 2018

Vesa Aaltonen

1 reference

25 March 2018

Sulevi Kaipiainen

1 reference

25 March 2018

Nina Laitamäki

1 reference

25 March 2018

Marko Ollila

1 reference

25 March 2018

Jari Rantanen

1 reference

25 March 2018

Satu Välimäki

1 reference

25 March 2018

Raija Sipilä

1 reference

25 March 2018

Tanja Laukkala

1 reference

25 March 2018

Jorma Komulainen

1 reference

25 March 2018

Petri Tommila

1 reference

25 March 2018

Ilkka Immonen

1 reference

25 March 2018

Anja Tuulonen

1 reference

25 March 2018

Kai Kaarniranta

1 reference

25 March 2018

publication date

1 July 2017

1 reference

25 March 2018

published in

Acta Ophthalmologica

1 reference

25 March 2018

volume

1 reference

25 March 2018

issue

A105 Suppl

1 reference

25 March 2018

page(s)

1-9

1 reference

25 March 2018

A study comparing two protocols of treatment with intravitreal bevacizumab (Avastin) for neovascular age-related macular degeneration

cites work

1 reference

Adverse events with intravitreal injection of vascular endothelial growth factor inhibitors: nested case-control study.

21 January 2018

1 reference

Mitochondrial DNA polymorphism A4917G is independently associated with age-related macular degeneration

21 January 2018

1 reference

Optical coherence tomography for the diagnosis of neovascular age-related macular degeneration: a systematic review

21 January 2018

1 reference

Optical coherence tomography for the monitoring of neovascular age-related macular degeneration: a systematic review

21 January 2018

1 reference

Intravitreal aflibercept for treatment-resistant neovascular age-related macular degeneration

21 January 2018

1 reference

Bevacizumab versus ranibizumab for neovascular age-related macular degeneration: a meta-analysis of randomized controlled trials.

21 January 2018

1 reference

Ranibizumab and bevacizumab for treatment of neovascular age-related macular degeneration: two-year results

21 January 2018

1 reference

Burden of illness of neovascular age-related macular degeneration in Canada

21 January 2018

1 reference

Cost-effectiveness of ranibizumab and bevacizumab for age-related macular degeneration: 2-year findings from the IVAN randomised trial.

21 January 2018

1 reference

Risk of scar in the comparison of age-related macular degeneration treatments trials

21 January 2018

1 reference

Complement factor H polymorphism and age-related macular degeneration

21 January 2018

1 reference

Fixed-interval versus OCT-guided variable dosing of intravitreal bevacizumab in the management of neovascular age-related macular degeneration: a 12-month randomized prospective study

21 January 2018

1 reference

The cost-utility of aflibercept for the treatment of age-related macular degeneration compared to bevacizumab and ranibizumab and the influence of model parameters

21 January 2018

1 reference

Endophthalmitis after resident-performed intravitreal bevacizumab injection

21 January 2018

1 reference

Early initial clinical experience with intravitreal aflibercept for wet age-related macular degeneration

21 January 2018

1 reference

Meta-analysis of infectious endophthalmitis after intravitreal injection of anti-vascular endothelial growth factor agents

21 January 2018

1 reference

TREAT-AND-EXTEND REGIMENS WITH ANTI-VEGF AGENTS IN RETINAL DISEASES: A Literature Review and Consensus Recommendations

21 January 2018

1 reference

Seven new loci associated with age-related macular degeneration

21 January 2018

1 reference

Risk of geographic atrophy in the comparison of age-related macular degeneration treatments trials

21 January 2018

1 reference

Complement factor H variant increases the risk of age-related macular degeneration

21 January 2018

1 reference

Safety study of 38,503 intravitreal ranibizumab injections performed mainly by physicians in training and nurses in a hospital setting

21 January 2018

1 reference

Ranibizumab combined with verteporfin photodynamic therapy in neovascular age-related macular degeneration: year 1 results of the FOCUS Study.

21 January 2018

1 reference

Intravitreal aflibercept (VEGF trap-eye) in wet age-related macular degeneration.

21 January 2018

1 reference

Twenty-four-month efficacy and safety of 0.5 mg or 2.0 mg ranibizumab in patients with subfoveal neovascular age-related macular degeneration

21 January 2018

1 reference

Agreement among ophthalmologists in evaluating fluorescein angiograms in patients with neovascular age-related macular degeneration for photodynamic therapy eligibility (FLAP-study).

21 January 2018

1 reference

Incidence of exudative age-related macular degeneration among elderly Americans

21 January 2018

1 reference

Ranibizumab for age-related macular degeneration: a meta-analysis of dose effects and comparison with no anti-VEGF treatment and bevacizumab

21 January 2018

1 reference

Treating peripapillary choroidal neovascular membranes: a review of the evidence

21 January 2018

1 reference

A variant of mitochondrial protein LOC387715/ARMS2, not HTRA1, is strongly associated with age-related macular degeneration

21 January 2018

1 reference

Strategies for improving early detection and diagnosis of neovascular age-related macular degeneration.

21 January 2018

1 reference

The epidemiology of age-related macular degeneration

21 January 2018

1 reference

Complement factor H polymorphism in age-related macular degeneration

21 January 2018

1 reference

Further observations on the association between smoking and the long-term incidence and progression of age-related macular degeneration: the Beaver Dam Eye Study.

21 January 2018

1 reference

Relation of smoking, drinking, and physical activity to changes in vision over a 20-year period: the Beaver Dam Eye Study

21 January 2018

1 reference

EVEREST study: efficacy and safety of verteporfin photodynamic therapy in combination with ranibizumab or alone versus ranibizumab monotherapy in patients with symptomatic macular polypoidal choroidal vasculopathy.

21 January 2018

1 reference

Factors Associated with Recurrence of Age-Related Macular Degeneration after Anti-Vascular Endothelial Growth Factor Treatment: A Retrospective Cohort Study.

21 January 2018

1 reference

Delay to treatment and visual outcomes in patients treated with anti-vascular endothelial growth factor for age-related macular degeneration

21 January 2018

1 reference

Bevacizumab in age-related macular degeneration: a randomized controlled trial on the effect of injections every 4 weeks, 6 weeks and 8 weeks

21 January 2018

1 reference

Quality of Life in Patients Suffering from Active Exudative Age-Related Macular Degeneration: The EQUADE Study

21 January 2018

1 reference

Meta-analysis of endophthalmitis after intravitreal injection of anti-vascular endothelial growth factor agents: causative organisms and possible prevention strategies.

21 January 2018

1 reference

Is it necessary to use three mandatory loading doses when commencing therapy for neovascular age-related macular degeneration using bevacizumab? (BeMOc Trial).

21 January 2018

1 reference

Five-year incidence of age-related maculopathy lesions: the Blue Mountains Eye Study

21 January 2018

1 reference

Optical coherence tomography for the diagnosis, monitoring and guiding of treatment for neovascular age-related macular degeneration: a systematic review and economic evaluation.

21 January 2018

1 reference

Five-year incidence of age-related maculopathy: the Visual Impairment Project

21 January 2018

1 reference

Agreement among Canadian retina specialists in the determination of treatment eligibility for photodynamic therapy in age-related macular degeneration

21 January 2018

1 reference

A 4-year longitudinal study of 555 patients treated with ranibizumab for neovascular age-related macular degeneration

21 January 2018

1 reference

Visual outcomes in relation to time to treatment in neovascular age-related macular degeneration

21 January 2018

1 reference

Ranibizumab for neovascular age-related macular degeneration

21 January 2018

1 reference

21 January 2018

1 reference

Efficacy and adverse events of aflibercept, ranibizumab and bevacizumab in age-related macular degeneration: a trade-off analysis

21 January 2018

1 reference

Guidelines for the management of neovascular age-related macular degeneration by the European Society of Retina Specialists (EURETINA).

21 January 2018

1 reference

Intravitreal aflibercept injection for neovascular age-related macular degeneration: ninety-six-week results of the VIEW studies

21 January 2018

1 reference

A safety audit of the first 10 000 intravitreal ranibizumab injections performed by nurse practitioners

21 January 2018

1 reference

A single-arm, investigator-initiated study of the efficacy, safety and tolerability of intravitreal aflibercept injection in subjects with exudative age-related macular degeneration, previously treated with ranibizumab or bevacizumab: 6-month [...]

21 January 2018

1 reference

A single-arm, investigator-initiated study of the efficacy, safety, and tolerability of intravitreal aflibercept injection in subjects with exudative age-related macular degeneration previously treated with ranibizumab or bevacizumab (ASSESS study):

21 January 2018

1 reference

Burden and health care resource utilization in neovascular age-related macular degeneration: findings of a multicountry study.

21 January 2018

1 reference

Diagnostic evaluation of type 2 (classic) choroidal neovascularization: optical coherence tomography, indocyanine green angiography, and fluorescein angiography

21 January 2018

1 reference

Systemic vascular safety of ranibizumab for age-related macular degeneration: systematic review and meta-analysis of randomized trials

21 January 2018

1 reference

The diagnostic accuracy of spectral-domain optical coherence tomography for neovascular age-related macular degeneration: a comparison with fundus fluorescein angiography

21 January 2018

1 reference

Prospective Trial of Treat-and-Extend versus Monthly Dosing for Neovascular Age-Related Macular Degeneration: TREX-AMD 1-Year Results

21 January 2018

1 reference

Photodynamic therapy versus anti-vascular endothelial growth factor agents for polypoidal choroidal vasculopathy: a meta-analysis

21 January 2018

1 reference

Improvement in vision-related function with intravitreal aflibercept: data from phase 3 studies in wet age-related macular degeneration.

21 January 2018

1 reference

Variability among retina specialists in evaluating fluorescein angiograms of patients with neovascular age-related macular degeneration

21 January 2018

1 reference

21 January 2018

Identifiers

DOI

10.1111/AOS.13501

1 reference

25 March 2018

1 reference

25 March 2018